creative medical technology holdings, inc., through its subsidiaries, engages in the stem cell research and developing applications to treat male sexual dysfunction and related issues. the company markets its erectile dysfunction (ed) treatment under the caverstem name to physicians for use with their patients suffering from ed. creative medical technology holdings, inc. was incorporated in 1998 and is based in phoenix, arizona. creative medical technology holdings, inc. is a subsidiary of creative medical health, inc.
Company profile
Ticker
CELZ
Exchange
Website
CEO
Timothy Warbington
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
JOLLEY MARKETING INC
SEC CIK
Corporate docs
Subsidiaries
StemSpine Inc. • ImmCelz Inc. • Creative Medical Technologies Inc. • AmnioStem LLC ...
CELZ stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
22 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
20 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
DEF 14A
Definitive proxy
3 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements
28 Jun 23
8-K
Creative Medical Technology Holdings Announces Reverse Stock Split
9 Jun 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
31 Mar 23
Latest ownership filings
4
Timothy Warbington
29 Jun 23
SC 13G/A
Markey John
26 May 23
SC 13G
Markey John
1 May 23
4
Timothy Warbington
23 Nov 22
4
Michael H. Finger
29 Sep 22
4
Timothy Warbington
28 Sep 22
4
Timothy Warbington
22 Sep 22
4
Michael H. Finger
14 Jun 22
4
Timothy Warbington
7 Jun 22
4
Michael H. Finger
20 May 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.51 mm | 4.51 mm | 4.51 mm | 4.51 mm | 4.51 mm | 4.51 mm |
Cash burn (monthly) | (no burn) | 1.04 mm | 514.40 k | 843.85 k | 434.84 k | 810.34 k |
Cash used (since last report) | n/a | 7.13 mm | 3.53 mm | 5.79 mm | 2.98 mm | 5.56 mm |
Cash remaining | n/a | -2.62 mm | 977.64 k | -1.28 mm | 1.52 mm | -1.05 mm |
Runway (months of cash) | n/a | -2.5 | 1.9 | -1.5 | 3.5 | -1.3 |
Institutional ownership, Q3 2023
50.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 3 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 100.12 mm |
Total shares | 679.98 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 332.32 k | $0.00 |
L1 Capital Global Opportunities Master Fund | 327.46 k | $724.00 k |
Vanguard | 17.63 k | $86.74 mm |
Tower Research Capital | 1.42 k | $7.01 mm |
UBS UBS Group AG - Registered Shares | 1.09 k | $5.37 mm |
WFC Wells Fargo & Co. | 30.00 | $147.00 k |
MS Morgan Stanley | 20.00 | $98.00 k |
IFP Advisors | 5.00 | $25.00 k |
Advisor | 3.00 | $15.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Jun 23 | Warbington Timothy | Common Stock | Buy | Acquire P | No | No | 4.36 | 200 | 872.00 | 12,209 |
27 Jun 23 | Warbington Timothy | Common Stock | Buy | Acquire P | No | No | 4.48 | 200 | 896.00 | 12,009 |
27 Jun 23 | Warbington Timothy | Common Stock | Buy | Acquire P | No | No | 4.45 | 300 | 1.34 k | 11,809 |
27 Jun 23 | Warbington Timothy | Common Stock | Buy | Acquire P | No | No | 4.4 | 300 | 1.32 k | 11,509 |
22 Nov 22 | Warbington Timothy | Common Stock | Buy | Acquire P | No | No | 0.3771 | 200 | 75.42 | 112,087 |
22 Nov 22 | Warbington Timothy | Common Stock | Buy | Acquire P | No | No | 0.39 | 9,800 | 3.82 k | 111,887 |
21 Nov 22 | Warbington Timothy | Common Stock | Buy | Acquire P | No | No | 0.393 | 5,000 | 1.97 k | 102,087 |
21 Nov 22 | Warbington Timothy | Common Stock | Buy | Acquire P | No | No | 0.4 | 10,000 | 4.00 k | 97,087 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
7 Mar 24
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
7 Mar 24
Why Is Diabetes Focused Creative Medical Stock Surging On Thursday?
7 Mar 24
12 Health Care Stocks Moving In Thursday's Intraday Session
7 Mar 24
Creative Medical Technology Holdings Inc. Announces FDA Authorization For Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
7 Mar 24
Press releases
Creative Medical Technology Holdings Provides Corporate Update
27 Mar 24
Market Momentum: NASDAQ SmallCaps Sparking Waves in March 2024: CELZ, DYAI, GROM, VTAK, BREA
8 Mar 24
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
7 Mar 24
Biotech Finds Mid-Week Success Following FDA Announcement
6 Mar 24
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
6 Mar 24